• Nektar Therapeutics granted non-qualified stock options for 11,900 shares to five newly hired employees under its 2025 Inducement Plan.
• Options were granted May 20, 2026 with an exercise price of $69.49 per share.
• Awards carry an eight-year term with four-year vesting: 25% after one year, then monthly vesting over the next three years.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nektar Therapeutics published the original content used to generate this news brief via PR Newswire (Ref. ID: SF74990) on June 03, 2026, and is solely responsible for the information contained therein.